# Safety of Administering Isoniazid to SLE Patients to Prevent TB

> **NCT06618573** · PHASE2,PHASE3 · RECRUITING · sponsor: **Universitas Padjadjaran** · enrollment: 60 (estimated)

## Conditions studied

- Tuberculosis
- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Isoniazid/Pyridoxine
- **DRUG:** Saccharum Lactis

## Key facts

- **NCT ID:** NCT06618573
- **Lead sponsor:** Universitas Padjadjaran
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-15
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06618573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06618573, "Safety of Administering Isoniazid to SLE Patients to Prevent TB". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06618573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*